FIGURE 4.

Normalised pathway scores, concentrations and chemical structures for thromboxane (TXA₂) and isoprostane metabolites in “symptom-low (n=30)” versus “symptom-high (n=61)”, T2-low participants. Samples taken from scheduled study visits and restricted to participants who were T2-low. a) Boxplot for isoprostane metabolite concentrations in “symptom-low” versus “symptom-high”, T2-low participants. b) Boxplot for metabolite concentrations in “symptom-low (ACQ-7 ≤1.5)” versus “symptom-high (ACQ-7 >1.5)”, T2-low participants. c) Violin plots for thromboxane (TXA₂) and isoprostane pathway scores in “symptom-low (ACQ-7 ≤1.5)” and “symptom-high (ACQ-7 >1.5)”, T2-low participants. d) Chemical structures of thromboxane (TXA₂) and isoprostane metabolites in panels a and b. T2-low: fractional exhaled nitric oxide <20 ppb and blood eosinophil count 0.15×10⁹ cells·L⁻¹; symptom-high: ACQ-7 >1.5; symptom-low: ACQ-7 ≤1.5. ACQ-7: asthma control quesionnaire-7. Outlying values were excluded if they were more than 1.5 times the IQR below the first quartile (Q1) or more than 1.5 times the IQR above the third quartile (Q3).